Literature DB >> 17670401

NT-proBNP in cardiac surgery: a new tool for the management of our patients?

Guillermo Reyes1, Gloria Forés, R Hugo Rodríguez-Abella, Gregorio Cuerpo, José Luis Vallejo, Carlos Romero, Angel Pinto.   

Abstract

OBJECTIVES: Our aim was to determine NT-proBNP levels in patients undergoing cardiac surgery and if those levels are related to any of the baseline clinical characteristics of patients before surgery or any of the outcomes or events after surgery.
METHODS: Prospective, analytic study including 83 consecutive patients undergoing cardiac surgery. Preoperatory and postoperatory data were collected. NT-proBNP levels were measured before surgery, the day of surgery, twice the following day and every 24 h until a total of nine determinations. Venous blood was obtained by direct venipuncture and collected into serum separator tubes. Samples were centrifuged within 20 min from sampling and stored for a maximum of 12 h at 2-8 degrees C before the separation of serum. Serum was stored frozen at -40 degrees C and thawed only once at the time of analysis.
RESULTS: Mean age was 65+/-11.8 years. An Euroscore 6 was found in 30% of patients. NYHA classification was as follows: I:27.7%; II:47%; III:25.3%. Preoperative atrial fibrilation occurred in 20.5% of patients. After surgery 18.1% of patients required inotropes. Only one death was recorded. A great variability was found in preoperative NT-proBNP levels; 759.9 (S.D.:1371.1); CI 95%: 464.9 to 1054.9 pg/ml, with a wide range (6.39-8854). Median was 366.5 pg/ml. Preoperative NT-proBNP levels were unrelated to the type of surgery (CABG vs. others), sex, age and any of the cardiovascular risk factors. NT-proBNP levels were higher in high risk patients (Euroscore 6); (P=0.021), worse NYHA class (P=0.020) and patients with preoperative atrial fibrilation (m 1767 (2205) vs m 621 (1017); P=0.001). After surgery NT-proBNP levels started increasing the following day until the fourth day (P=0.03), decreasing afterwards (P=0.019). These levels were significantly higher in patients requiring inotropes after surgery (P<0.001). We did not find any relationship between NT-proBNP levels and complications rate (P=0.59).
CONCLUSIONS: Preoperative NT-proBNP levels depend on preoperative patient status (Euroscore, NYHA class and cardiac rhythm) and they increase significantly after cardiac surgery. This increase is higher when postoperative inotropes are needed. We found no relation between NT-proBNP levels and complications rate. An association have been shown between NT-proBNP levels and the use of inotropes after cardiac surgery.

Entities:  

Year:  2005        PMID: 17670401     DOI: 10.1510/icvts.2004.101576

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  N-terminal pro-Brain natriuretic peptide as a useful biomarker for monitoring prognosis in patients with cardiac valve replacement.

Authors:  Bei Cai; Lanlan Wang; Jin Liu; Yingkang Shi; Yingqiang Guo
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

2.  NT-proBNP and postoperative heart failure in surgery for aortic stenosis.

Authors:  Huiqi Jiang; Farkas Vánky; Henrik Hultkvist; Jonas Holm; Yanqi Yang; Rolf Svedjeholm
Journal:  Open Heart       Date:  2019-05-22

3.  Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study.

Authors:  Huiqi Jiang; Jonas Holm; Örjan Friberg; Farkas Vanky; Mårten Vidlund; Bashir Tajik; Yanqi Yang; Rolf Svedjeholm
Journal:  Perioper Med (Lond)       Date:  2021-07-13

4.  Rise and fall of NT-proBNP in aortic valve intervention.

Authors:  Henrik Hultkvist; Jonas Holm; Rolf Svedjeholm; Farkas Vánky
Journal:  Open Heart       Date:  2018-04-01

5.  The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study.

Authors:  Huiqi Jiang; Jonas Holm; Mårten Vidlund; Farkas Vanky; Örjan Friberg; Yanqi Yang; Rolf Svedjeholm
Journal:  J Transl Med       Date:  2020-05-11       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.